Pathfinder Cell Therapy Inc
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies… Read more
Pathfinder Cell Therapy Inc (PFND) - Net Assets
Latest net assets as of September 2015: $-6.73 Million USD
Based on the latest financial reports, Pathfinder Cell Therapy Inc (PFND) has net assets worth $-6.73 Million USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.00K) and total liabilities ($6.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.73 Million |
| % of Total Assets | -17256.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -4535.07% |
| Growth Volatility | 2848.43 |
Pathfinder Cell Therapy Inc - Net Assets Trend (1999–2014)
This chart illustrates how Pathfinder Cell Therapy Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pathfinder Cell Therapy Inc (1999–2014)
The table below shows the annual net assets of Pathfinder Cell Therapy Inc from 1999 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-5.94 Million | -30.59% |
| 2013-12-31 | $-4.55 Million | -59.63% |
| 2012-12-31 | $-2.85 Million | -303.25% |
| 2011-12-31 | $-707.00K | +27.34% |
| 2010-12-31 | $-973.00K | -215.56% |
| 2009-12-31 | $842.00K | -71.00% |
| 2008-12-31 | $2.90 Million | +3.09% |
| 2007-12-31 | $2.82 Million | -15.36% |
| 2006-12-31 | $3.33 Million | +2382.84% |
| 2005-12-31 | $134.00K | -90.92% |
| 2004-12-31 | $1.48 Million | +8100.00% |
| 2003-12-31 | $18.00K | +102.86% |
| 2002-12-31 | $-630.00K | +53.02% |
| 2001-12-31 | $-1.34 Million | -67.83% |
| 2000-12-31 | $-799.00K | +19.37% |
| 1999-12-31 | $-991.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pathfinder Cell Therapy Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1794800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $667.00K | % |
| Other Components | $11.83 Million | % |
| Total Equity | $-5.94 Million | 100.00% |
Pathfinder Cell Therapy Inc Competitors by Market Cap
The table below lists competitors of Pathfinder Cell Therapy Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spyglass Resources Corp
PINK:SGLRF
|
$0.99 |
|
Odyne Corporation
PINK:ODYC
|
$0.99 |
|
Helmer Directional
PINK:EXLA
|
$0.99 |
|
Avistar Communications Corp
PINK:AVSR
|
$0.99 |
|
City Bank
PINK:CTBK
|
$0.99 |
|
AgriMinco Corp
PINK:ETPHF
|
$0.99 |
|
Zane Interactive Publishing Inc
PINK:ZNAE
|
$0.99 |
|
M Line Hldgs Inc
PINK:MLHC
|
$0.99 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pathfinder Cell Therapy Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -4,551,000 to -5,943,000, a change of -1,392,000.
- Net loss of 1,669,000 reduced equity.
- Other factors increased equity by 277,000.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.67 Million | -28.08% |
| Other Changes | $277.00K | +4.66% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pathfinder Cell Therapy Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-0.11 | $0.00 | x |
| 2000-12-31 | $-0.08 | $0.00 | x |
| 2001-12-31 | $-0.10 | $0.00 | x |
| 2002-12-31 | $-0.04 | $0.00 | x |
| 2003-12-31 | $0.00 | $0.00 | x |
| 2004-12-31 | $0.03 | $0.00 | x |
| 2005-12-31 | $0.00 | $0.00 | x |
| 2006-12-31 | $0.04 | $0.00 | x |
| 2007-12-31 | $0.03 | $0.00 | x |
| 2008-12-31 | $0.03 | $0.00 | x |
| 2009-12-31 | $0.01 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $-0.01 | $0.00 | x |
| 2014-12-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pathfinder Cell Therapy Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-713.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | -79.52% | 1.51x | 0.00x | $-855.90K |
| 2000 | 0.00% | -896.55% | 0.06x | 0.00x | $-440.10K |
| 2001 | 0.00% | -2080.00% | 0.08x | 0.00x | $-593.90K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-985.00K |
| 2003 | -8761.11% | 0.00% | 0.00x | 56.33x | $-1.58 Million |
| 2004 | -124.73% | 0.00% | 0.00x | 1.53x | $-1.99 Million |
| 2005 | -1602.99% | 0.00% | 0.00x | 8.13x | $-2.16 Million |
| 2006 | -117.07% | -2742.96% | 0.03x | 1.26x | $-4.23 Million |
| 2007 | -164.17% | -3450.00% | 0.04x | 1.20x | $-4.90 Million |
| 2008 | -151.71% | -2433.15% | 0.05x | 1.15x | $-4.69 Million |
| 2009 | -487.29% | -1139.72% | 0.29x | 1.45x | $-4.19 Million |
| 2010 | 0.00% | -603.49% | 2.37x | 0.00x | $-1.98 Million |
| 2011 | 0.00% | -25920.55% | 0.11x | 0.00x | $-18.85 Million |
| 2012 | 0.00% | -1975.44% | 0.32x | 0.00x | $-1.97 Million |
| 2013 | 0.00% | -3353.70% | 0.35x | 0.00x | $-1.36 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.07 Million |
Industry Comparison
This section compares Pathfinder Cell Therapy Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pathfinder Cell Therapy Inc (PFND) | $-6.73 Million | 0.00% | N/A | $0.99 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |